We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+44.05%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$250M
Cap. Flow
+$59M
Cap. Flow %
5.51%
Top 10 Hldgs %
62.56%
Holding
47
New
20
Increased
3
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$71.3M
2
UTHR icon
United Therapeutics
UTHR
+$69.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$67.9M
4
GMED icon
Globus Medical
GMED
+$52.3M
5
KROS icon
Keros Therapeutics
KROS
+$35.1M

Top Sells

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$48M
2
MRSN
Mersana Therapeutics
MRSN
+$46M
3
CGEN icon
Compugen
CGEN
+$42.9M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$36.4M
5
APRE icon
Aprea Therapeutics
APRE
+$35.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.27%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIOX
26
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$8.86M 0.83%
3,186,335
-50,000
-2% -$146K
CLRB icon
27
Cellectar Biosciences
CLRB
$20.5M
$8.47M 0.79%
+13,580
New +$6.24M
CTIC
28
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$8.09M 0.76%
+2,512,800
New +$8.36M
COGT icon
29
Cogent Biosciences
COGT
$7.24B
$6.85M 0.64%
+610,000
New +$6.7M
DFHTU
30
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
$3.75M 0.35%
250,000
– –
JYAC
31
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$3.09M 0.29%
+300,000
New +$3.05M
ADMA icon
32
ADMA Biologics
ADMA
$2.22B
$3.04M 0.28%
1,558,290
– –
TNGX icon
33
Tango Therapeutics
TNGX
$4.41B
$2.06M 0.19%
180,000
– –
MLTX icon
34
MoonLake Immunotherapeutics
MLTX
$1.55B
$1.69M 0.16%
+150,000
New +$1.59M
FSDC
35
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$1.1M 0.1%
100,000
– –
ATNM icon
36
Actinium Pharmaceuticals
ATNM
$25M
$690K 0.06%
88,428
-704,742
-89% -$7.66M
CERE
37
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$658K 0.06%
+39,697
New +$516K
YMAB
38
DELISTED
Y-mAbs Therapeutics
YMAB
$301K 0.03%
+6,073
New +$281K
APRE icon
39
Aprea Therapeutics
APRE
$8.05M
– –
-72,971
Closed -$35.1M
CGEN icon
40
Compugen
CGEN
$228M
– –
-2,637,421
Closed -$42.9M
HRTX icon
41
Heron Therapeutics
HRTX
$92.9M
– –
-2,005,218
Closed -$29.7M
KNSA icon
42
Kiniksa Pharmaceuticals
KNSA
$5.93B
– –
-2,374,392
Closed -$36.4M
OMER icon
43
Omeros
OMER
$959M
– –
-484,042
Closed -$4.89M
SLNO
44
DELISTED
Soleno Therapeutics
SLNO
– –
-202,667
Closed -$7.63M
LMNL
45
DELISTED
Liminal BioSciences Inc. Common Shares
LMNL
– –
-308,463
Closed -$34.3M
MTEM
46
DELISTED
Molecular Templates, Inc.
MTEM
– –
-115,734
Closed -$19M
APTO
47
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-17,766
Closed -$48M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Consonance Capital Management held 47 positions worth $1.07B, up 30% from $821M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Consonance Capital Management deployed $59M of net new capital in Q4 2020, opening 20 new positions and adding to 3 existing holdings. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 330,000 shares worth $72.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $46M trimmed.

  • Consonance Capital Management's largest Q4 2020 buy was Mirati Therapeutics, Inc. Common Stock: 330,000 shares worth $72.5M.
  • Consonance Capital Management added most to SpringWorks Therapeutics in Q4 2020, an estimated $18.7M increase.
  • Consonance Capital Management's biggest Q4 2020 reduction was Mersana Therapeutics, cutting an estimated $46M.
  • Consonance Capital Management fully exited Aptose Biosciences, Inc. in Q4 2020, selling an estimated $48M.
  • Consonance Capital Management's ten largest holdings make up 63% of its $1.07B portfolio in Q4 2020.
  • Consonance Capital Management opened 20 new positions and closed 9 in Q4 2020.
  • Consonance Capital Management's portfolio value rose 30% quarter-over-quarter to $1.07B.

Based on Consonance Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.